Shandong Sinobioway Biomedicine (002581.SZ) has obtained the ethical approval for Phase III clinical trials of a class of innovative drugs, recombinant human nerve growth factor SMR001 eye drops.

Shandong Sinobioway Biomedicine (002581.SZ) announced that its wholly-owned subsidiary, Shandong Yandu Biotechnology Co., Ltd., has received approval from the Ethics Committee of Beijing Tongren Hospital, Capital Medical University, to conduct a critical Phase III registration clinical trial for its self-developed innovative drug Recombinant Human Nerve Growth Factor SMR001 eye drops (referred to as "SMR001 eye drops") for the treatment of moderate to severe dry eye syndrome. The approval of the ethics approval for the Phase III clinical trial of SMR001 eye drops represents that the project has the ethical compliance foundation to conduct clinical trials, and is not expected to have a significant impact on the company's operational performance in the short term.